We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Titan Pharmaceuticals Inc | NASDAQ:TTNP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0401 | -0.59% | 6.8099 | 6.55 | 6.81 | 6.81 | 6.60 | 6.81 | 1,459 | 16:54:10 |
|
Delaware
(State or other jurisdiction of incorporation or organization) |
| |
2836
(Primary Standard Industrial Classification Code Number) |
| |
94-3171940
(I.R.S. Employer Identification Number) |
|
|
Fran Stoller
Loeb & Loeb LLP 345 Park Avenue New York, New York 10154 Telephone: (212) 407-4000 |
| |
Barry L. Grossman
Sarah E. Williams Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas New York, NY 10105 (212) 370-1300 |
|
| Large accelerated filer ☐ | | | Accelerated filer ☐ | | | Non-accelerated filer ☒ | | |
Smaller reporting company ☒
Emerging growth company ☐ |
|
| | |
Per Unit
|
| |
Total
|
| ||||||
Public offering(1)
|
| | | $ | | | | | $ | | | ||
Underwriting discounts and commissions(2)
|
| | | $ | | | | | $ | | | ||
Proceeds to us, before expenses
|
| | | $ | | | | | $ | | | |
Description
|
| |
Page
|
| |||
| | | | 1 | | | |
| | | | 6 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 21 | | | |
| | | | 24 | | | |
| | | | 24 | | | |
| | | | 24 | | | |
| | | | 25 | | |
|
Assumed combined public offering price per unit
|
| | | | | | | | | $ | 0.1372 | | |
|
Net tangible book value per share as of June 30, 2020
|
| | | $ | 0.0160 | | | | | | | | |
|
Increase in net tangible book value per share after this offering
|
| | | | 0.0368 | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | | 0.0528 | | |
|
Dilution per share to new investors
|
| | | | | | | | | $ | (0.0844) | | |
Underwriter
|
| |
Number of Units
|
| |||
Maxim Group LLC
|
| | | | | | |
| | | | | | | |
Total
|
| | | | | | |
| | |
Per
Unit(1) |
| |
Total
|
| |
Total with Full
Exercise of Overallotment |
|
Public offering price
|
| | | | | | | | | |
Underwriting discount to be paid to the underwriters by us (6.0%)(2)
|
| | | | | | | | | |
Proceeds to us (before expenses)
|
| | | | | | | | | |
|
SEC registration fee
|
| | | $ | 1,248.40 | | |
|
FINRA filing fee
|
| | | | 2,216.41 | | |
|
Legal fees and expenses
|
| | | | 50,000.00 | | |
|
Accounting fees and expenses
|
| | | | 25,000.00 | | |
|
Underwriters’ out-of-pocket expenses
|
| | | | 50,000.00 | | |
|
Printing expenses
|
| | | | 15,000.00 | | |
|
Other (including transfer agent and registrar fees)
|
| | | | 6,535.19 | | |
|
Total
|
| | | $ | 150,000.00 | | |
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Marc Rubin, M.D.
Marc Rubin, M.D.
|
| |
Executive Chairman
(principal executive officer and principal financial officer) |
| |
October 27, 2020
|
|
|
/s/ Kate DeVarney, Ph.D.
Kate DeVarney, Ph.D.
|
| |
President, Chief Operating Officer and Director
|
| |
October 27, 2020
|
|
|
*
Joseph A. Akers
|
| | Director | | |
October 27, 2020
|
|
|
/s/ Sunil Bhonsle
Sunil Bhonsle
|
| | Director | | |
October 27, 2020
|
|
|
*
M. David MacFarlane, Ph.D.
|
| | Director | | |
October 27, 2020
|
|
|
*
James R. McNab, Jr.
|
| | Director | | |
October 27, 2020
|
|
|
*
Scott A. Smith
|
| | Director | | |
October 27, 2020
|
|
|
/s/ Brian E. Crowley
Brian E. Crowley
|
| |
Vice President, Finance
(principal accounting officer) |
| |
October 27, 2020
|
|
|
* By:
Kate DeVarney, Ph.D.
Kate DeVarney, Ph.D.,
Attorney-in-fact |
| | |
1 Year Titan Pharmaceuticals Chart |
1 Month Titan Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions